IN THE CLAIMS:

Please cancel claims 1-15 and add new claims 16-33 as shown below in the detailed listing of all claims which are, or were, in the application:

1-15 (cancelled).

16. (New) A method for preventing or halting cellular proliferation in a person or an animal, comprising administering an effective amount of said *cis*-urocanic acid in an essentially non-dissociated form to the person or animal in the form of a pharmaceutical composition.

17. (New) The method of claim 16, wherein said *cis*-urocanic acid has a dissociation constant in the range of 5.0 to 7.4.

18. (New) The method of claim 17, wherein said dissociation constant is in the range of 6.0 to 7.3.

19. (New) The method of claim 18, wherein said dissociation constant is about 7.0.

20. (New) The method of claim 16, wherein said person or animal is in need of treatment or prevention of a disease or disorder which is curable by intracellular acidification inducing the inhibition or halting of cell proliferation.

21. (New) The method of claim 20, wherein the disease or disorder is a local or systemic, non-transformed or transformed hyperproliferative disease.

22. (New) The method of claim 21, wherein the disease or disorder is a local or systemic cancer selected from brain, lung, skin, bladder, gastric, pancreatic, breast, head, neck, kidney, ovarian, prostate, colorectal, oesophageal, gynaecological and thyroid cancer.

23. (New) The method of claim 16, wherein the *cis*-urocanic acid is administered systemically or locally.

24. (New) The method of claim 23, wherein said *cis*-urocanic acid is administered locally.

25. (New) The method of claim 24, wherein said *cis*-urocanic acid is administered topically.

26. (New) A method for enhancing the effect of a therapeutically active agent, comprising administering said therapeutically active agent to a human or animal in need of said treatment in combination with *cis*-urocanic acid.

27. (New) Pharmaceutical composition comprising a therapeutically active agent, an enhancer for said agent and a pharmaceutically acceptable agent being able to acidify the cell cytoplasm, in combination with a pharmaceutically acceptable carrier, which carrier essentially prevents the enhancer from dissociating at extracellular pH values.

28. (New) The composition of claim 27, wherein said enhancer is an agent having its dissociation constant in the range 5.0 to 7.4.

29. (New) The composition of claim 28, wherein said dissociation constant is in the range 6.0 to 7.3.

30. (New) The composition of claim 29, wherein said dissociation constant is about 7.0.

31. (New) The composition of claim 27, wherein said enhancer is *trans*-urocanic acid.

32. (New) The composition of claim 27, wherein said enhancer is *cis*-urocanic acid.

33. (New) The composition of claim 27, wherein the therapeutically active agent is an anti-proliferative or anticancer agent.